Monthly Archives: July 2018

Breakfast Technical Briefing on Regency Centers and Three Other Additional REIT – Retail Stocks

Stock Research Monitor: O, DDR, and EPR

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on REG sign up now at www.wallstequities.com/registration. On Monday, July 30, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday’s session. The NASDAQ Composite ended the day at 7,630.00, down 1.39%; the Dow Jones Industrial Average edged 0.57% lower, to finish at 25,306.83; and the S&P 500 closed at 2,802.60, down 0.58%. This Tuesday morning, WallStEquities.com looks at the performance of these four REIT – Retail stocks: Realty Income Corp. (NYSE: O), Regency Centers Corp. (NYSE: REG), DDR Corp. (NYSE: DDR), and EPR Properties (NYSE: EPR). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Realty Income

On Monday, shares in Realty Income Corp. recorded a trading volume of 1.50 million shares. The stock ended the session 0.60% higher at $55.37. The Company’s shares have gained 9.62% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.67% and 3.88%, respectively. Moreover, shares of Realty Income, which engages in in-house acquisition, portfolio management, asset management, credit research, real estate research, legal, finance and accounting, information technology and capital markets capabilities, have a Relative Strength Index (RSI) of 54.78. Get the full research report on O for free by clicking below at:

www.wallstequities.com/registration/?symbol=O

Regency Centers

Regency Centers Corp.’s stock closed the day 1.34% higher at $62.70 with a total trading volume of 1.64 million shares, which was above their three months average volume of 1.29 million shares. The Company’s shares have advanced 6.54% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.15% and 1.69%, respectively. Additionally, shares of Regency Centers, which includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers, have an RSI of 60.10. REG’s complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=REG

DDR Corp.

Shares in DDR Corp. recorded a trading volume of 1.45 million shares. The stock ended yesterday’s trading session 2.43% higher at $13.49. The Company’s shares have advanced 12.71% over the previous three months. The stock is trading above its 200-day moving averages by 2.71%. Furthermore, shares of DDR Corp., which owns a high-quality portfolio of open-air shopping centers in major metropolitan areas that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers, have an RSI of 44.15.

On July 03rd, 2018, research firm Stifel reiterated its ‘Hold’ rating on the Company’s stock with a decrease of the target price from $17 a share to $14.25 a share. Register for your free research report on DDR at:

www.wallstequities.com/registration/?symbol=DDR

EPR Properties

EPR Properties’ stock finished Monday’s session 0.64% higher at $66.20 with a total trading volume of 424,687 shares. The Company’s shares have advanced 20.32% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.57% and 6.86%, respectively. Additionally, shares of EPR Properties, which invests in properties in select market segments which require unique industry knowledge, while offering the potential for stable and attractive returns, have an RSI of 58.08.

On July 20th, 2018, research firm Raymond James initiated a ‘Market Perform’ rating on the Company’s stock. Wall St. Equities’ downloadable research report on EPR available at:

www.wallstequities.com/registration/?symbol=EPR

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507465

Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities

Stock Research Monitor: PLX, RDUS, and RIGL

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Monday, the NASDAQ Composite ended the day at 7,630.00, down 1.39%; the Dow Jones Industrial Average edged 0.57% lower, to finish at 25,306.83; and the S&P 500 closed at 2,802.60, marginally slipping 0.58%. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Protalix BioTherapeutics

Karmiel, Israel-based Protalix BioTherapeutics Inc.’s stock finished Monday’s session 2.96% lower at $0.49 with a total trading volume of 942,635 shares, which was higher than their three months average volume of 570.38 thousand shares. The stock has gained 10.28% in the past month and 18.35% over the past three months. The Company’s shares are trading above their 50-day moving average by 7.51%. Moreover, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have a Relative Strength Index (RSI) of 56.92. Get the full research report on PLX for free by clicking below at:

www.wallstequities.com/registration/?symbol=PLX

Radius Health

Shares in Waltham, Massachusetts headquartered Radius Health Inc. declined 2.30%, ending yesterday’s session at $24.18 with a total trading volume of 682,814 shares. The Company’s shares are trading below their 50-day moving average by 16.69%. Moreover, shares of Radius Health, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 28.48. Today’s complimentary research report on RDUS is accessible at:

www.wallstequities.com/registration/?symbol=RDUS

Rigel Pharmaceuticals

On Monday, South San Francisco, California-based Rigel Pharmaceuticals Inc.’s stock saw a drop of 1.07%, to close the day at $2.78. A total volume of 2.13 million shares was traded. The Company’s shares have advanced 19.31% over the last twelve months. The stock is trading below its 50-day moving average by 14.20%. Additionally, shares of Rigel Pharma, which engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases, have an RSI of 40.60. Register now for your free research document on RIGL at:

www.wallstequities.com/registration/?symbol=RIGL

Sarepta Therapeutics

Shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. ended the day 3.21% lower at $115.31. A total volume of 1.52 million shares was traded. The stock has gained 51.01% in the previous three months and 182.55% over the last twelve months. The Company’s shares are trading above their 200-day moving average by 47.44%. Furthermore, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases, have an RSI of 33.61. Click on the link below and see our free report SRPT at:

www.wallstequities.com/registration/?symbol=SRPT

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507466

Today’s Free Research Reports Coverage on Life Storage and Three More Semiconductor – Specialized Stocks

Stock Research Monitor: SEDG, VSLR, and VVPR

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on LSI sign up now at www.wallstequities.com/registration. On Monday, July 30, 2018, the NASDAQ Composite ended the trading session at 7,630.00, down 1.39%; the Dow Jones Industrial Average edged 0.57% lower, to finish at 25,306.83; and the S&P 500 closed at 2,802.60, slightly dropping 0.58%. Losses were broad based as seven out of nine sectors ended the day in negative. This Tuesday, WallStEquities.com has initiated reports coverage on the following Semiconductor – Specialized equities: Life Storage Inc. (NYSE: LSI), SolarEdge Technologies Inc. (NASDAQ: SEDG), Vivint Solar Inc. (NYSE: VSLR), and VivoPower International PLC (NASDAQ: VVPR). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Life Storage

Buffalo, New York-located Life Storage Inc.’s stock finished Monday’s session 0.58% higher at $95.13 with a total trading volume of 329,341 shares. The Company’s shares have advanced 30.51% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 0.33% and 8.72%, respectively. Additionally, shares of Life Storage, which operates more than 700 storage facilities in 28 states, have a Relative Strength Index (RSI) of 46.70. Get the full research report on LSI for free by clicking below at:

www.wallstequities.com/registration/?symbol=LSI

SolarEdge Technologies

On Monday, shares in Herzliya, Israel headquartered SolarEdge Technologies Inc. recorded a trading volume of 840,131 shares. The stock ended the session 1.76% lower at $53.00. The Company’s shares have advanced 132.46% over the last twelve months. The stock is trading above its 200-day moving average by 15.19%. Moreover, shares of SolarEdge Technologies, which together with its subsidiaries, designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations in Israel, the US, the Netherlands, Europe, and internationally, have an RSI of 47.99. Free research on SEDG can be accessed at:

www.wallstequities.com/registration/?symbol=SEDG

Vivint Solar

Lehi, Utah headquartered Vivint Solar Inc.’s shares closed the day 2.61% lower at $5.60. The stock recorded a trading volume of 372,738 shares. The Company’s shares have gained 14.29% in the last month and 41.77% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 17.38% and 41.84%, respectively. Additionally, shares of Vivint Solar, which provides distributed solar energy to residential, commercial, and industrial customers in the US, have an RSI of 58.10. Visit WallStEquities.com now and sign up for the free research on VSLR at:

www.wallstequities.com/registration/?symbol=VSLR

VivoPower International

Shares in London, the UK headquartered VivoPower International PLC finished 1.31% lower at $1.51. The stock recorded a trading volume of 21,449 shares. The Company’s shares have advanced 7.86% in the previous three months. The stock is trading below its 50-day moving average by 29.00%. Furthermore, shares of VivoPower International, which together with its subsidiaries, develops and operates installed solar power assets in the UK, the US, Australia, and internationally, have an RSI of 34.76. The free technical report on VVPR is available at:

www.wallstequities.com/registration/?symbol=VVPR

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507467

GelTech’s DAN SIMON to Co-Present at the iP Utility Safety Conference in Orlando, FL in November 2018

JUPITER, FL / ACCESSWIRE / July 31, 2018 / GelTech Solutions, Inc. (OTCQB: GLTC) an innovator in the use of environmentally-friendly polymers for fire suppression and prevention, is pleased to announce that Dan Simon, its Chief Operating Officer and Director of Utility Markets, will be a co-presenter with PECO senior methods specialists at the iP Utility Safety Conference. PECO, based in Philadelphia is part of the Excelon family of electric utilities with subsidiaries in Chicago, Washington DC, Atlantic City and Baltimore. The title of the paper being presented at the conference is “Safety in the Event of a Manhole Explosion.”

The paper and presentation is a follow up to the recently published cover article “Innovative Fire Suppression Solutions – For System and Worker Safety” in the June/July issue of Incident Prevention magazine. The article, co-authored by Edward Morson and Mark Green, both senior methods specialists at PECO, highlights PECO’s implementation of FireIce products into their worker safety program. The implementation is the culmination of a two-year collaboration between PECO and GelTech Solutions to determine how FireIce products can be effectively used to address the unique fire hazards that utility workers face. In addition, the article explains the exhaustive testing performed and the objectives of PECO to meet their needs in several areas of the Utilities Safety goals.

http://online.incident-prevention.com/publication/?i=504188&ver=html5&p=18

The November conference session will explore how to keep employees and the public safe during a manhole event. Learning objectives will include best practices for approaching and gaining control of a manhole event, how to protect employees and other assets within the structure during an event including egress and will include how the best practices and FireIce gel may also be used for overhead events. The presentation will also include a comparison of dry chemicals to gel.

Dan Simon served as Emergency Manager for Con Edison in Manhattan for over 40 years before joining GelTech Solutions. During his time at ConEd, he oversaw underground emergency restoration and provided technical and system expertise during multiple crises, including the World Trade Center and Hurricane Katrina.

About GelTech Solutions, Inc.

Founded by inventor and Chief Technology Officer Peter Cordani, GelTech Solutions is a leading provider of innovative, environmentally friendly and cost-effective products that help government agencies, industry, agriculture and the public achieve goals such as water conservation and protecting lives, homes and property from fires. GelTech’s products include FireIce, a non-corrosive polymer that when hydrated produces a water-based suppressant to extinguish fires and a retardant to protect assets and property; Soil2O Dust Control products that reduce airborne particulate matter with minimal environmental impact; and GT-W14, an advanced absorbency technology to control fluid spills of all sizes, turning liquids into solid waste for easier and safer disposal. For more information on GelTech, please visit www.geltechsolutions.com.

For more information about GelTech, please visit www.GelTechSolutions.com

For more information about FireIce, please visit www.FireIce.com

For Investor Relations, please contact:

Michael Porter
Porter, LeVay & Rose
212-564-4700
michael@plrinvest.com

For media or product inquiries, please contact:

Paul Christle, Director of Media and Communications
GelTech Solutions, Inc.
800-924-4874
pchristle@geltechsolutions.com

SOURCE: GelTech Solutions, Inc.

ReleaseID: 507408

Change Financial Ends June Quarter Prepared for New Phase of Growth

SYDNEY, AUSTRALIA and LOS ANGELES, CA / ACCESSWIRE / July 31, 2018 / U.S-based fintech, banking software, and blockchain investment company, Change Financial Limited (ASX: CCA) (OTCQX: CNGFF) (“Change Financial” or “the Company”) is pleased to present its quarterly report for the three months ending 30 June 2018.

Restructured leadership for a new phase of growth

Operationally, a significant portion of the June quarter was devoted to Change Financial’s restructure of its leadership and capital raising for a strategic acquisition of the Ivy Entities (‘Ivy’), as the Company embarks on a new phase of growth.

On July 4, Change Financial announced that they had appointed Eric Bachman as CEO effective 1 August 2018, with Managing Director Ash Shilkin remaining on the Board and moving to an Executive Director. Mr. Bachman is an institutional payments veteran with over 30 years’ experience in banking, payments, and building new companies. Mr. Bachman’s experience reaches across key brands, such as Wells Fargo, US Bank, Visa, BankServ, and NextCard. He was part of the team that built and launched Marqeta’s leading payment card issuing and processing services and analytics platform. With the support of key leadership which includes alumni of Westpac, PayPal and Goldman Sachs, Mr. Bachman is ideally placed to lead Change Financial to execute its monetization strategy and bring its enterprise solution to market.

Capital raising and acquisition of Ivy

To support its evolution, in early July, Change Financial raised approximately US$2.62 million in a heavily oversubscribed placement. Net proceeds from the placement are being used to fund working capital, the deployment and marketing of its enterprise solution and for the purchase of the option to acquire Ivy (US$250,000).

Ivy is developing a platform which aims to solve one of cryptocurrency’s biggest challenges, the issue of anonymity associated with payments recorded on a blockchain and how they interact with the existing financial ecosystem. Ivy’s platform will embed comprehensive Know-your-Customer (KYC) and Know-your-Transaction (KYT) information into the Ivy token to assist in the satisfaction of anti-money laundering (AML) requirements. The aim of Ivy’s technology is to bridge the gap between the significant volume of blockchain-based payments (up to US$92 million in the US alone in 2017 according to Bloomberg) and financial institutions. Furthermore, the vision for Ivy is to ultimately be an alternative to the global incumbent payment networks which transfer more than US$5 trillion per day[1].

Change Financial intends to integrate the Ivy platform into its enterprise solution and award-winning consumer product as it continues to evolve its unified payments platform. Further to this, Ivy announced during the quarter a partnership with HiveEx, a leading cryptocurrency trading platform, to launch IvyPay, a platform which will turn cryptocurrency into AUD instantly and allow it to be used to make payments.

Finalized testing of the enterprise solution

Change Financial made further progress towards the launch of its enterprise solution which will provide turn-key services targeting 7,000 Federal Deposit Insurance Corporation (FDIC) banks in the US with innovative, cost-effective mobile banking services. Incoming CEO Mr. Bachman has six years of experience with Marqeta successfully rolling out similar product offerings; Marqeta recently achieved a valuation of US$545 million.

The Company has been working with its partners Mastercard (MA), Discovery Financial Services’ (DFS) subsidiary Pulse and the Central Bank of Kansas City to become one of the small number of processors that is fully integrated with Mastercard globally. Change Financial completed interconnection testing during the quarter and, post the quarter end, began testing programs for registration as a Mastercard third-party processor, including system messaging, key exchange and transactional testing.

Change Financial is on track to begin testing customer accounts and is targeting a full launch in 2H FY19. Change Financial expects the appointment of Mr. Bachman, who has extensive experience and connections in the payments industry, will greatly expedite the progress of the enterprise solution as it moves through development into full launch.

The size of the addressable market for the enterprise solution is extremely large, with the global payments industry projected to grow its revenues to $2.2 trillion annually by 2021, driven by global GDP growth and the increasing transactional needs of businesses and consumers worldwide[2].

Strategic review of consumer product underway

Change Financial’s award-winning consumer mobile banking app, ChimpChange, achieved total transaction volume (TTV) of US$35 million with deposits of US$11.9 million and a continued record efficiency of cost of acquiring customers (CAC) of just US$10 per customer. Compared to the prior comparable period (June quarter 2017), loads were up 39%, purchases were up 37% up and TTV was up 40%. ChimpChange not only provides an excellent customer-facing mobile banking solution but also supports the Company’s SaaS enterprise solution by providing a valuable testing ground for forging mobile banking best practices.

Change Financial is currently conducting a strategic review of ChimpChange which includes evaluating additional monetization opportunities and the exploration of other methods of unlocking value from its customer base.

Cash flow

Cash at the end of the June quarter was $1.67 million. All financial figures in the following Appendix 4C, Quarterly Cash Flow Report as filed with the Australian Stock Exchange, are denominated in US dollars, unless stated otherwise. Furthermore, after the close of the quarter, as mentioned above, the Company completed a raise of US$2.62 million through a private placement.

Change Financial Executive Director Ash Shilkin: “I am excited by the opportunities presented by our enterprise solution and the Ivy business. I am confident Mr. Bachman will be effective in leading our strong team as we challenge and disrupt the payments industry. We look forward to integrating our consumer, enterprise and blockchain capabilities in a way that delivers on our promise of creating better banking through technology.”

About Change Financial

Change Financial Limited (ASX: CCA) (OTCQX: CNGFF) is a US-focused fintech company revolutionizing the way traditional currencies and digital assets flow between consumers, businesses and financial institutions through its range of innovative, globally scalable payments’ services. Change Financial’s solutions include a registered Mastercard enterprise processor, a blockchain-based payments platform and cryptocurrency and an award-winning consumer digital banking platform.

To learn more, please visit: www.changefinancial.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Change Financial Limited’s Consumer, Enterprise, Blockchain and blockchain (including its interest in IvyKoin) divisions. All forward-looking statements contained in this press release are subject to various risks and uncertainties that could materially affect these matters including, without limitation, whether the acquisition proposal will result in a negotiated agreement, and if so, whether that agreement will be consummated. In addition, the Company’s most recent annual report and other financial reports and filings with the Australian Securities Exchange, available on its website www.changefinancial.com contain disclosures about important risks and uncertainties that may affect the Company’s business, and investors may wish to refer to those filings for Change Financial Limited’s statements regarding such matters.

Footnotes:

[1] https://www.fincen.gov/sites/default/files/shared/Appendix_D.pdf
[2] https://www.mckinsey.com/~/media/McKinsey/Industries/Financial%20Services/Our%20Insights/A%20mixed%202015%20for%20the%20global%20payments%20industry/Global-Payments-2016.ashx

For more information, please contact:

Investors and Media (US)

Mark Collinson, Compass Investor Relations
mcollinson@compass-ir.com
714.222.5161

Investors and Media (Australia)

Julia Maguire, The Capital Network
julia@thecapitalnetwork.com.au
+61 419.815.386

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of Entity: Change Financial Limited

ABN: 34 150 762 351

Quarter ended (“current quarter”): 30 June 2018

Consolidated statement of cash flows

Current quarter

$US’000

Year to date (12 months)

$US’000

1.

Cash flows from operating activities

193

877

1.1

Receipts from customers

1.2

Payments for

(877
)

(3,312
)

(a)staff costs

(b)advertising and marketing

(157
)

(1,934
)

(c)other

(735
)

(3,837
)

1.3

Dividends received (see note 3)

1.4

Interest received

3

24

1.5

Interest and other costs of finance paid

1.6

Income taxes paid

1.7

Government grants and tax incentives

77

158

1.8

Other (provide details if material)

1.9

Net cash from / (used in) operating activities

(1,496
)

(8,024
)

2.

Cash flows from investing activities

2.1

Payments to acquire:

(a)software

(29
)

(274
)

(b)payment for investment

(c)physical non-current assets

(100

(4

)

)

(100

(16

)

)

2.2

Proceeds from disposal of:

(a)property, plant and equipment

(b)businesses (see item 10)

(c)investments

(d)intellectual property

(e)other non-current assets

2.3

Cash flows from loans to other entities

2.4

Dividends received (see note 3)

2.5

Other (provide details if material)

2.6

Net cash from / (used in) investing activities

(33
)

(390
)

+ See Chapter 19 for defined terms
1 September 2016

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

3.

Cash flows from financing activities

3.1

Proceeds from issues of shares

3.2

Proceeds from issue of convertible notes

3.3

Proceeds from exercise of share options

686

3.4

Transaction costs related to issues of shares, convertible notes or options

3.5

Proceeds from borrowings

3.6

Repayment of borrowings

3.7

Transaction costs related to loans and borrowings

3.8

Dividends paid

3.9

Other (provide details if material)

3.10

Net cash from / (used in) financing activities

0

686

4.

Net increase / (decrease) in cash and cash equivalents for the period

4.1

Cash and cash equivalents at beginning of quarter/year to date

3,245

9,468

4.2

Net cash from / (used in) operating activities (item 1.9 above)

(1,496
)

(8,024
)

4.3

Net cash from / (used in) investing activities (item 2.6 above)

(33
)

(390
)

4.4

Net cash from / (used in) financing activities (item 3.10 above)

0

686

4.5

Effect of movement in exchange rates on cash held

(44
)

(68
)

4.6

Cash and cash equivalents at end of quarter

1,672

1,672

+ See Chapter 19 for defined terms
1 September 2016

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

5.

Reconciliation of cash and cash equivalents

at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts

Current quarter

$US’000

Previous quarter

$US’000

5.1

Bank balances

1,672

3,245

5.2

Call deposits

5.3

Bank overdrafts

5.4

Other (provide details)

5.5

Cash and cash equivalents at end of quarter (should equal item 4.6 above)

1,672

3,245

6.

Payments to directors of the entity and their associates

Current quarter

$US’000

6.1

Aggregate amount of payments to these parties included in item 1.2

102

6.2

Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3

Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Item 6.1 comprises payments to the Directors including remuneration paid to the Managing Director.

+ See Chapter 19 for defined terms
1 September 2016

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

7.

Payments to related entities of the entity and their associates

Current quarter

$US’000

7.1

Aggregate amount of payments to these parties included in item 1.2

7.2

Aggregate amount of cash flow from loans to these parties included in item 2.3

7.3

Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.

Financing facilities available

Add notes as necessary for an understanding of the position

Total facility amount at quarter end

$US’000

Amount drawn at quarter end

$US’000

8.1

Loan facilities

8.2

Credit standby arrangements

8.3

Other (please specify)

8.4

Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

+ See Chapter 19 for defined terms
1 September 2016

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

9.

Estimated cash outflows for next quarter

$US’000

9.1

Research and development

9.2

Product manufacturing and operating costs

9.3

Advertising and marketing

(196
)

9.4

Leased assets

9.5

Staff costs

(823
)

9.6

Administration and corporate costs

9.7

Purchase of Ivy Option

(250
)

9.8

Other (provide details if material)

(294
)

9.9

Total estimated cash outflows

(1,563
)

10.

Acquisitions and disposals of business entities

(items 2.1(b) and 2.2(b) above)

Acquisitions

Disposals

10.1

Name of entity

10.2

Place of incorporation or registration

10.3

Consideration for acquisition or disposal

10.4

Total net assets

10.5

Nature of business

+ See Chapter 19 for defined terms
1 September 2016

Compliance statement

This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
This statement gives a true and fair view of the matters disclosed.

By Order of the Board,

Gillian Nairn, Company Secretary
30 June 2018

Notes

The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

SOURCE: Change Financial Limited

ReleaseID: 507461

Blockchain Industries Announces Advisory Agreement With BLAKFX

The BLAKFX ICO Will Offer BLAKCOIN for Faster, More Secure Transactions

SANTA MONICA, CA / ACCESSWIRE / July 31, 2018 / Blockchain Industries, Inc. (OTC PINK: BCII) today announced its agreement with BLAKFX to be lead advisor for their initial coin offering (ICO). Per the agreement, Blockchain Industries may receive potential fees and revenue in excess of $10 million in the form of cash, BLAKCOIN tokens, and/or cryptocurrency for its advisory services.

BLAKFX’s ICO will offer BLAKCOIN, a highly secure crypto coin. Based on cryptographic technology, BLAKCOIN differentiates itself by offering five layers of encryption, including two layers that provide quantum computing attack immunity; the industry standard is two layers of encryption. With pioneering levels of security and efficiency, BLAKCOIN aims to be the first hack-proof digital asset. Strategic partners can launch new coins via BLAKFX’s crypto software at a reduced cost, operating within a reliable ecosystem on a secure platform without risk of interception or theft.

“The BLAKFX team, led by Dr. Statica, has developed something truly remarkable,” said Patrick Moynihan, CEO of Blockchain Industries. “Hacking theft and fraud are hampering growth in the digital ledger technology industry. When you aim to eliminate hacking threats within a full security ecosystem and offer two layers of protection that provide quantum computing attack immunity, it seems governments, multinational corporations, and institutional investors pay attention and consider the far-reaching implications to their citizens, companies, countries, and overall industries.”

With advanced levels of protection, BLAKCOIN expects to be guarded against theft, tampering, interception, and transaction denials, as each transaction receives five randomly generated ciphers as well as perfect forward security (PFS) for every key exchange. It also features advances in transaction speeds, scalability, ledger synchronization, and throughput.

The most innovative feature of the BLAKFX ecosystem is its ability to host all ERC20 (the protocol for proposing improvements to the Ethereum network) and native tokens on its platform with full BLAKFX security features. This ability breaks new ground in the field, opening up a higher level of crypto-asset security to the entire industry.

“We are excited to work with Blockchain Industries to bring the BLAKFX protocol and suite of products to market,” said Dr. Robert Statica, CEO & President of BLAKFX. “Their merchant bank model for international crypto asset markets is the perfect fit for our global initiative and alternative banking payment systems. Our team has worked extensively to solve the intolerable hacking issue in our field, and we look forward to furthering this work with Blockchain Industries.”

About Blockchain Industries, Inc.

Blockchain Industries, Inc. is a publicly traded merchant bank focused on the international blockchain and cryptocurrency sectors. The company is comprised of an ICO Advisory, an Investment Management arm, and a Global Conference Series (Blockchain Unbound) connecting entrepreneurs and investors. The company is headquartered in Santa Monica, California, with satellite offices in New York, Puerto Rico, and Tokyo.

For more information on Blockchain Industries, visit http://www.blockchainind.com.

About BLAKFX

BLAFX is a private entity backed by cutting-edge technology and built by founders with over 40 years of providing the world’s most sophisticated cyber security solutions for consumers, enterprise, military, governments and high net-worth individuals. With security and efficiency improvements to the Blockchain, BLAKFX is building the next generation and ultra-secure crypto coin, wallet and exchange – BLAKCoin, BLAKWallet, BLAKXchange. BLAKFX solves security and liquidity problems troubling Bitcoin, Ethereum and Ripple with a secure platform and distributed exchange for high-frequency trading of digital fiat and tokens. The company protects cryptos in transit and at rest enabling all coins to flourish free of interception and theft. The company is based in New York, with offices in New Jersey and Dubai.

For more information on BLAKFX, visit https://www.blakcoin.org.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. We caution readers that forward-looking statements are predictions based on our current expectations about future events. Forward looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “aim” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to revise or update any forward-looking statement for any reason.

SOURCE: Blockchain Industries, Inc.

ReleaseID: 507487

Joint Compound Market 2018 Global Industry Growth and Key Manufacturers Analysis

Global Joint Compound Market, 2018 Industry Research Report presents the company profile, product specifications, demands, future trends, sales, capacity, production value and 2018-2023 market shares for each company.

Pune, India – July 31, 2018 /MarketersMedia/

Global and Chinese Joint Compound Market, 2013-2023 Industry Research Report is a professional and in-depth study on the current state of the global Joint Compound industry with a focus on the Chinese market. The report provides key statistics on the market status of the Joint Compound manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the Joint Compound Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail.

In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Joint Compound industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2018-2023 market development trends of Joint Compound industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Joint Compound Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2023 global and Chinese Joint Compound industry covering all important parameters.

Complete report of Joint Compound Market research report Includes 140 pages profiling 8 companies and supported with 98 tables available at http://www.reportsnreports.com/contacts/discount.aspx?name=1582798

Major Points from Table of Contents

Chapter One Introduction of Joint Compound Industry
1.1 Brief Introduction of Joint Compound
1.2 Development of Joint Compound Industry
1.3 Status of Joint Compound Industry

Chapter Two Manufacturing Technology of Joint Compound
2.1 Development of Joint Compound Manufacturing Technology
2.2 Analysis of Joint Compound Manufacturing Technology
2.3 Trends of Joint Compound Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers

Chapter Four 2013-2018 Global and Chinese Market of Joint Compound
4.1 2013-2018 Global Capacity, Production and Production Value of Joint Compound Industry
4.2 2013-2018 Global Cost and Profit of Joint Compound Industry
4.3 Market Comparison of Global and Chinese Joint Compound Industry
4.4 2013-2018 Global and Chinese Supply and Consumption of Joint Compound
4.5 2013-2018 Chinese Import and Export of Joint Compound

Chapter Five Market Status of Joint Compound Industry
5.1 Market Competition of Joint Compound Industry by Company
5.2 Market Competition of Joint Compound Industry by Country (USA, EU, Japan, Chinese etc.)
5.3 Market Analysis of Joint Compound Consumption by Application/Type

Order a Copy of this Research Report at http://www.reportsnreports.com/purchase.aspx?name=1582798

Chapter Six 2018-2023 Market Forecast of Global and Chinese Joint Compound Industry
6.1 2018-2023 Global and Chinese Capacity, Production, and Production Value of Joint Compound
6.2 2018-2023 Joint Compound Industry Cost and Profit Estimation
6.3 2018-2023 Global and Chinese Market Share of Joint Compound
6.4 2018-2023 Global and Chinese Supply and Consumption of Joint Compound
6.5 2018-2023 Chinese Import and Export of Joint Compound

Chapter Seven Analysis of Joint Compound Industry Chain
7.1 Industry Chain Structure
7.2 Upstream Raw Materials
7.3 Downstream Industry

Chapter Eight Global and Chinese Economic Impact on Joint Compound Industry
8.1 Global and Chinese Macroeconomic Environment Analysis
8.1.1 Global Macroeconomic Analysis
8.1.2 Chinese Macroeconomic Analysis
8.2 Global and Chinese Macroeconomic Environment Development Trend
8.2.1 Global Macroeconomic Outlook
8.2.2 Chinese Macroeconomic Outlook
8.3 Effects to Joint Compound Industry

Chapter Nine Market Dynamics of Joint Compound Industry
9.1 Joint Compound Industry News
9.2 Joint Compound Industry Development Challenges
9.3 Joint Compound Industry Development Opportunities

Chapter Ten Proposals for New Project
10.1 Market Entry Strategies
10.2 Countermeasures of Economic Impact
10.3 Marketing Channels
10.4 Feasibility Studies of New Project Investment

Chapter Eleven Research Conclusions of Global and Chinese Joint Compound Industry

List of Tables and Figures.

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Feel free to Call us at + 1 888 391 5441 or Email us at sales@reportsandreports.com

Contact Info:
Name: Hrishikesh Patwardhan
Email: sales@reportsandreports.com
Organization: ReportsnReports
Address: 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001
Phone: + 1 888 391 5441

Source URL: https://marketersmedia.com/joint-compound-market-2018-global-industry-growth-and-key-manufacturers-analysis/387004

For more information, please visit http://www.reportsnreports.com/reports/1582798-global-and-chinese-joint-compound-industry-2018-market-research-report.html

Source: MarketersMedia

Release ID: 387004

Down Syndrome Pipeline Market 2018 Analysis, Drug target, Mechanism Of Action

Down Syndrome Pipeline Market Review, H2 2018 report presents pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.

Pune, India – July 31, 2018 /MarketersMedia/

The latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome Pipeline Market Review, H2 2018, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Pharmaceutical and Healthcare latest pipeline guide Down Syndrome Pipeline Market Review, H2 2018, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

This report is available at 20% Discount for Single User License till 03 August 2018. To avail this report at http://www.reportsnreports.com/purchase.aspx?name=1582273

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For more details Inquire at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1582273

List of Tables
Number of Products under Development for Down Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Down Syndrome – Pipeline by AC Immune SA, H2 2018
Down Syndrome – Pipeline by Aelis Farma SAS, H2 2018
Down Syndrome – Pipeline by Eisai Co Ltd, H2 2018
Down Syndrome – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Down Syndrome – Pipeline by ManRos Therapeutics, H2 2018
Down Syndrome – Pipeline by NeuroNascent Inc, H2 2018
Down Syndrome – Pipeline by QR Pharma Inc, H2 2018
Down Syndrome – Dormant Projects, H2 2018
Down Syndrome – Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Down Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Contact Info:
Name: Hrishikesh Patwardhan
Email: sales@reportsandreports.com
Organization: ReportsnReports
Address: 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001
Phone: + 1 888 391 5441

Source URL: https://marketersmedia.com/down-syndrome-pipeline-market-2018-analysis-drug-target-mechanism-of-action/386999

For more information, please visit http://www.reportsnreports.com/reports/1582273-down-syndrome-pipeline-review-h2-2018.html

Source: MarketersMedia

Release ID: 386999

Energy Measurement ICs Market Analytical Overview, Leading Players Update, Growth Analysis, Development History by Forecast to 2022

Global Energy Measurement ICs Information, Functions (Active Energy, Apparent Energy, Reactive Energy), By Type (Single Channel, Multi-Channel), By Application (Smart Plugs, Industrial, Smart appliances, Smart Homes, Smart Cities) – Forecast 2018-2022

Pune, India – July 31, 2018 /MarketersMedia/

Market Highlights:

Global Energy Measurement ICs market is seeing various opportunities in the coming future. Deployment and high adoption rate of smart appliances, project for smart cities and increasing awareness about the low energy consumption in homes are driving the market. This market has been valued at US high million and as the application areas for the energy measurement ICs are increasing, it is expected that market will reach mark of US high million.

Get Sample Report @
https://www.marketresearchfuture.com/sample_request/1681

High adoption rate of technology is leading to high consumption of energy which is causing various other problems. Energy Measurement ICs are computerized chip which helps to plan the power schedule and responsible for the effective management of energy in and out. Manufacturing industries are dealing with heavy demand which leads to deployment of extra machinery and business expansion. As tradition energy system consumes energy in very large amount, smart energy devices such as ICs are controlling the flow and helps is better management.

Competitor Players by Energy Measurement ICs Market:

The major participants of this market are Analog Devices, Inc. (U.S.), NXP Semiconductors (Netherlands), Cirrus Logic (U.S.), Maxim Integrated (U.S.), STMicroelectronics (Switzerland), Linear Technology (U.S.), Microchip Technology (U.S.), Atmel Corporation (U.S.), Integrated Device Technology, Inc. (U.S.) among others.

Market Research Analysis:

North America is dominating the market of Energy Measurement ICs. Presence of key global players in this region and advantage of having developed nation in this region is giving boost to the market in North America. Asia-Pacific has emerged as fastest growing market for the Energy Measurement ICs with CAGR of high. Growing economy of Asian countries such as India and China are supporting the market in Asia-Pacific.

Segments:

Global Energy Measurement ICs Market has been segmented on the basis of function/management which includes- active energy (kWh), apparent energy (kVA), reactive energy (kVAR) and RMS Energy. On the basis of type, the market has been segmented as Single-Channel and Multi-Channel. By verticals market has been segmented as- Smart plugs, Industrial, Power monitors for servers, Smart appliances, Smart Homes, Smart Cities among others.

Intended Audience

• IC Manufacturers
• Electric Meter Manufactures
• Power Generation Companies
• Power Distribution Companies
• Chip Manufacturers
• Government
• Smart ICs Suppliers and Manufactures

Table of Content
1 Market Introduction
1.1 Introduction
1.2 Scope of Study
1.2.1 Research Objective
1.2.2 Assumptions
1.2.3 Limitations
1.3 Market Structure:
1.3.1 Global Energy Measurement IC Market: By Function
1.3.2 Global Energy Measurement Ics Market: By Type
1.3.2 Global Energy Measurement Ics Market: By Application

2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
2.4 Forecast Model
2.4.1 Market Data Collection, Analysis & Forecast
2.4.2 Market Size Estimation
2.4.3 Market Crackdown & Data Triangulation
Continues…

Access Full Report @ https://www.marketresearchfuture.com/reports/energy-measurement-ics-market-1681
Study Objectives of Energy Measurement ICs Market:

• To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Energy Measurement ICs Market
• To provide insights about factors affecting the market growth
• To analyze the Energy Measurement ICs market based on various factors- supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW)
• To provide country level analysis of the market with respect to the current market size and future prospective
• To provide country level analysis of the market for segment by function, by type, by applications and sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Energy Measurement ICs Market

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Abhishek Sawant
Email: sales@marketresearchfuture.com
Organization: Market Research Future
Address: Market Research Future Office No. 528, Amanora Chambers Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL: https://marketersmedia.com/energy-measurement-ics-market-analytical-overview-leading-players-update-growth-analysis-development-history-by-forecast-to-2022/387002

For more information, please visit https://www.marketresearchfuture.com/reports/energy-measurement-ics-market-1681

Source: MarketersMedia

Release ID: 387002

Zooid Pesticide Market 2018 – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2025

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

Pune, India – July 31, 2018 /MarketersMedia/

This report studies the global Zooid Pesticide market status and forecast, categorizes the global Zooid Pesticide market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa).

The global Zooid Pesticide market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.

The major manufacturers covered in this report
Bayer
Syngenta
BASF
Monsanto
DOW
DuPont
ADAMA
FMC
Nufarm
Arysta
UPL
Mitsui Chemicals
Cheminova
Cheminova
Sumitomo chemical

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3284998-global-zooid-pesticide-market-research-report-2018

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
North America
Europe
China
Japan
Southeast Asia
India
Other Regions (India, Southeast Asia, Central & South America and Middle East & Africa)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Animal Toxin
Insect Hormone
Pheromone
Others

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Agriculture
Forestry
Others

Table of Contents

Global Zooid Pesticide Market Research Report 2018
1 Zooid Pesticide Market Overview
1.1 Product Overview and Scope of Zooid Pesticide
1.2 Zooid Pesticide Segment by Type (Product Category)
1.2.1 Global Zooid Pesticide Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
1.2.2 Global Zooid Pesticide Production Market Share by Type (Product Category) in 2017
1.2.3 Animal Toxin
1.2.4 Insect Hormone
1.2.5 Pheromone
1.2.6 Others
1.3 Global Zooid Pesticide Segment by Application
1.3.1 Zooid Pesticide Consumption (Sales) Comparison by Application (2013-2025)
1.3.2 Agriculture
1.3.3 Forestry
1.3.4 Others
1.4 Global Zooid Pesticide Market by Region (2013-2025)
1.4.1 Global Zooid Pesticide Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
1.4.2 Status and Prospect (2013-2025)
1.4.3 25 Status and Prospect (2013-2025)
1.4.4 North America Status and Prospect (2013-2025)
1.4.5 Europe Status and Prospect (2013-2025)
1.4.6 China Status and Prospect (2013-2025)
1.4.7 Japan Status and Prospect (2013-2025)
1.5 Global Market Size (Value) of Zooid Pesticide (2013-2025)
1.5.1 Global Zooid Pesticide Revenue Status and Outlook (2013-2025)
1.5.2 Global Zooid Pesticide Capacity, Production Status and Outlook (2013-2025)

2 Global Zooid Pesticide Market Competition by Manufacturers
2.1 Global Zooid Pesticide Capacity, Production and Share by Manufacturers (2013-2018)
2.1.1 Global Zooid Pesticide Capacity and Share by Manufacturers (2013-2018)
2.1.2 Global Zooid Pesticide Production and Share by Manufacturers (2013-2018)
2.2 Global Zooid Pesticide Revenue and Share by Manufacturers (2013-2018)
2.3 Global Zooid Pesticide Average Price by Manufacturers (2013-2018)
2.4 Manufacturers Zooid Pesticide Manufacturing Base Distribution, Sales Area and Product Type
2.5 Zooid Pesticide Market Competitive Situation and Trends
2.5.1 Zooid Pesticide Market Concentration Rate
2.5.2 Zooid Pesticide Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Zooid Pesticide Capacity, Production, Revenue (Value) by Region (2013-2018)
3.1 Global Zooid Pesticide Capacity and Market Share by Region (2013-2018)
3.2 Global Zooid Pesticide Production and Market Share by Region (2013-2018)
3.3 Global Zooid Pesticide Revenue (Value) and Market Share by Region (2013-2018)
3.4 Global Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.5 North America Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.6 Europe Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.7 China Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.8 Japan Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.9 Southeast Asia Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.10 India Zooid Pesticide Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

4 Global Zooid Pesticide Supply (Production), Consumption, Export, Import by Region (2013-2018)
4.1 Global Zooid Pesticide Consumption by Region (2013-2018)
4.2 North America Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.3 Europe Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.4 China Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.5 Japan Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.6 Southeast Asia Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.7 India Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.6 Southeast Asia Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.7 India Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.8 South America Zooid Pesticide Production, Consumption, Export, Import (2013-2018)
4.9 Middle East and Africa Zooid Pesticide Production, Consumption, Export, Import (2013-2018)

5 Global Zooid Pesticide Production, Revenue (Value), Price Trend by Type
5.1 Global Zooid Pesticide Production and Market Share by Type (2013-2018)
5.2 Global Zooid Pesticide Revenue and Market Share by Type (2013-2018)
5.3 Global Zooid Pesticide Price by Type (2013-2018)
5.4 Global Zooid Pesticide Production Growth by Type (2013-2018)

6 Global Zooid Pesticide Market Analysis by Application
6.1 Global Zooid Pesticide Consumption and Market Share by Application (2013-2018)
6.2 Global Zooid Pesticide Consumption Growth Rate by Application (2013-2018)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

……Continued

Access Complete Report @ https://www.wiseguyreports.com/reports/3284998-global-zooid-pesticide-market-research-report-2018

Contact Info:
Name: Norah Trent
Email: Sales@Wiseguyreports.Com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune – 411028 Maharashtra, India
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)

Source URL: https://marketersmedia.com/zooid-pesticide-market-2018-global-industry-analysis-size-share-growth-trends-and-forecast-2025/387005

For more information, please visit https://www.wiseguyreports.com/

Source: MarketersMedia

Release ID: 387005